ESRX
Express Scripts, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Nov. 11, 6:47 AM
    • Novartis (NYSE:NVS) upgraded to Buy from Hold with an $85 (15% upside) price target by Argus Research.
    • Humana (NYSE:HUM) upgraded to Overweight from Neutral with a $202 (5% upside) price target by JPMorgan.
    • McKesson (NYSE:MCK) upgraded to Buy from Neutral with a $147 (0% upside) price target by Mizuho Securities.
    • AmerisourceBergen (NYSE:ABC) upgraded to Buy from Neutral by Mizuho Securities. Price target raised to $89 (12% upside) from $84.
    • Healthways (NASDAQ:HWAY) upgraded to Buy from Sell by UBS Global Research. Price target raised to $24 (9% upside) from $22.50.
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) upgraded to Buy from Neutral by Bank of America. Price target lowered to $35 (22% upside) from $39.
    • Biogen (NASDAQ:BIIB) upgraded to Overweight from Neutral with a $335 (3% upside) price target by Piper Jaffray.
    • Juno Therapeutics (NASDAQ:JUNO) upgraded to Neutral from Sell by BTIG Research.
    • Express Scripts (NASDAQ:ESRX) upgraded to Hold from Sell by Deutsche Bank. Price target increased to $70 (7% downside risk) from $69.
    | Fri, Nov. 11, 6:47 AM | 4 Comments
  • Mon, Oct. 31, 11:36 AM
    • Shire plc (SHPG -3.3%) slumps in early trading on increased volume in apparent response to comments made by Express Scripts (ESRX +2.6%) Chief Medical Officer Steven Miller during a phone interview. He said the company is mulling ways to manage the rising costs of hemophilia medicines without forcing patients to switch treatments. Shire is a major player in the space after its merger with Baxalta. Hemophilia products accounted for over 46% of Baxalta's business in 2015.
    • Related tickers: (OTCPK:BAYRY -0.7%)(PFE -0.2%)(NVO -0.4%)(BMRN -0.6%)(BAX +0.9%)(BIIB -0.4%)(SGMO +1.4%)
    | Mon, Oct. 31, 11:36 AM | 3 Comments
  • Fri, Oct. 28, 7:13 PM
    • In a regulatory filing, Express Scripts (NASDAQ:ESRX) reports that it has received a letter from the U.S. Internal Revenue Service confirming the conclusion of its examination into the potential tax benefit related to the disposition of PolyMedica, a now-bankrupt firm that was owned by Medco, a company Express Scripts acquired for $29.1B in 2012.
    • This quarter, the company will recognize a $511M tax benefit which will increase GAAP EPS by $0.80 - 0.81, thereby upping Q4 guidance to $2.18 - 2.25. Non-GAAP EPS guidance of $1.84 - 1.90 will remain as is.
    | Fri, Oct. 28, 7:13 PM
  • Fri, Oct. 28, 11:22 AM
    • Drug wholesaler McKesson's (MCK -23.2%) lackluster Q3 numbers and softer guidance due to pricing pressure is weighing on the entire drug supply chain. Competitors AmerisourceBergen (ABC -11.9%) and Cardinal Health (CAH -11.2%) report next week.
    • Representative tickers: (ESRX -4.5%)(CVS -3.9%)(WBA -2.7%)(RAD -0.9%)(UNH +0.1%)
    | Fri, Oct. 28, 11:22 AM | 69 Comments
  • Wed, Oct. 26, 6:44 PM
    • The FDA's controversial approval of Sarepta Therapeutics' (NASDAQ:SRPT) eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping has translated into a difficult path to insurance coverage.
    • Humana says it will cover the $300K+ cost of therapy only for ambulatory DMD patients. Those who are wheelchair-bound or deteriorate to wheelchair status are apparently out of luck.
    • Anthem (NYSE:ANTM) has declined to cover it at all because it considers eteplirsen experimental despite the OK from the FDA.
    • Aetna (NYSE:AET) and Express Scripts (NASDAQ:ESRX) plan to conduct a full clinical review of the drug before deciding to cover. UnitedHealth Group (NYSE:UNH) is considering coverage with a prior authorization while Cigna (NYSE:CI) has only indicated interest in providing coverage.
    | Wed, Oct. 26, 6:44 PM | 35 Comments
  • Tue, Oct. 25, 4:24 PM
    • Express Scripts (NASDAQ:ESRX) Q3 results ($M): Total Revenues: 25,410.1 (+0.1%).
    • EBITDA: 1,948.1 (+11.7%); Non-GAAP EBITDA: 1,948.1 (+7.7%); Net Income: 722.9 (+9.2%); Non-GAAP Net Income: 1,091.6 (+10.3%); EPS: 1.15 (+18.6%); Non-GAAP EPS: 1.74 (+20.0%); CF Ops (9 mo.): 2,670.5 (+35.3%).
    • Claims Volume: 247.0 (-6.0%); Generic Fill Rate: 85.4% (+1.1%).
    • 2016 Guidance: EPS: $4.47 - 4.53 from $4.45 - 4.55; Non-GAAP EPS: $6.36 - 6.42 from $6.33 - 6.43; Operating Income: $5,105 - 5,180 from $5,135 - 5,250; Total Adjusted Claims: 1,265 - 1,280 from 1,260 - 1,290.
    • Q4 Guidance: EPS: $1.38 - 1.44; Non-GAAP EPS: $1.84 - 1.90.
    • 2017 Guidance: Retention rate: 97 - 98% from 96 - 98%.
    • Shares are up 2% after hours on average volume.
    | Tue, Oct. 25, 4:24 PM
  • Tue, Oct. 25, 4:02 PM
    • Express Scripts (NASDAQ:ESRX): Q3 EPS of $1.74 in-line.
    • Revenue of $25.4B (+0.7% Y/Y) misses by $90M.
    • Press Release
    | Tue, Oct. 25, 4:02 PM | 2 Comments
  • Mon, Oct. 24, 5:35 PM
    | Mon, Oct. 24, 5:35 PM | 20 Comments
  • Tue, Oct. 11, 8:21 AM
    | Tue, Oct. 11, 8:21 AM | 1 Comment
  • Mon, Aug. 1, 9:24 PM
    • Express Scripts (ESRX +0.1%) is adding new drugs to its excluded list, meaning some treatments from makers including Valeant (VRX -6.3%), Eli Lilly (LLY +0.4%), and Bristol-Myers Squibb (BMY +1.8%) won't be covered by insurance.
    • The 2017 list covers 85 excluded drugs, vs. 87 excluded in 2016, the company said.
    • Excluded drugs include Valeant's Zyclara skin cream for actinic keratosis; Bristol's arthritis drug Orencia, Lilly's Taltz psoriasis treatment and some brands of gout drug colchicine.
    • Meanwhile, previously excluded drugs like Pfizer's (PFE +1.1%) Xeljanz and Xeljanz XR arthritis treatments, and GlaxoSmithKline's (GSK +0.4%) Arnuity Ellipta and Floven Diskus asthma treatments, will be covered again.
    • Express Scripts says exclusions have provided for better negotiated prices and savings for customers of an estimated $1.8B in 2017.
    | Mon, Aug. 1, 9:24 PM | 76 Comments
  • Mon, Jul. 25, 5:11 PM
    • Express Scripts Holding (NASDAQ:ESRX) Q2 results ($M): Total Revenues: 25,222.3 (-1.0%);
    • EBITDA: 1,798.1 (+4.9%); Non-GAAP EBITDA: 1,798.1 (+0.2%); Net Income: 720.7 (+20.1%); Non-GAAP Net Income: 998.7 (+2.0%); EPS: 1.13 (+28.4%); Non-GAAP EPS: 1.57 (+9.0%); CF Ops (6 mo.): 1,190.1 (+0.7%).
    • Claims Volume: 250.7 (-3.0%);
    • 2016 Guidance: Total adjusted claims: 1,260 - 1,290 from 1,255 - 1,295; EBITDA: $7,230 - 7,430 (unch); Operating Income: $5,135 - 5,250 (unch); EPS: $4.45 - 4.55 from $4.53 - 4.61: Non-GAAP EPS: $6.33 - 6.43 from $6.31 - 6.43; CF Ops: $4,600 - 5,100 (unch).
    • Expected 2017 retention rate for 2016 selling season: 96 - 98%.
    • Shares are off a fraction after hours.
    | Mon, Jul. 25, 5:11 PM | 1 Comment
  • Mon, Jul. 25, 4:03 PM
    • Express Scripts (NASDAQ:ESRX): Q2 EPS of $1.57 in-line.
    • Revenue of $25.22B (-0.9% Y/Y) misses by $200M.
    • Shares -0.8%.
    • Press Release
    | Mon, Jul. 25, 4:03 PM
  • Sun, Jul. 24, 5:35 PM
    | Sun, Jul. 24, 5:35 PM | 5 Comments
  • Wed, Jul. 6, 7:12 PM
    • Express Scripts (NASDAQ:ESRX) hsa priced its any-and-all tender offer for outstanding notes due 2017.
    • The company is offering $1,011.30 per $1,000 of principal for its 2.65% senior notes due 2017, of which $1.5B is outstanding.
    • The offer expired today at 5 p.m. ET. Of the outstanding amount, $1.105B was validly tendered and the company accepted them for purchase. Settlement date is expected tomorrow.
    | Wed, Jul. 6, 7:12 PM
  • Sun, Jul. 3, 2:50 PM
    • via Barclays:
    • "Although stocks in the U.S. and Europe have partially bounced back from the sharp selloff sparked by the U.K. referendum result, risks remain prevalent. [Analyst] Keith Parker foresees further equity downside alongside a prolonged market bottoming process, during which positioning is likely to turn much more defensive at active managers.
    • "With this in mind, our stock screen this week highlights Overweight-rated stocks that screen defensively based on sector and equity beta but are also expected to generate superior ROE and free cash flows in FY1.
    • "Our screen considers the following factors: i) Large-cap (US $5 billion+) stock in the consumer staples, utilities, telecom or healthcare sectors. ii) Adjusted beta less than 1.0. iii) Rated Overweight by Barclays equity research. iv) 15%+ ROE and 4.5%+ FCF yield expected in FY1, based on Barclays estimates."
    • The stocks: Aetna (NYSE:AET), BT Group plc (NYSE:BT), Cardinal Health (NYSE:CAH), Coloplast (OTC:CLPBF, OTCPK:CLPBY), CVS (NYSE:CVS), Estee Lauder (NYSE:EL), Express Scripts (NASDAQ:ESRX), Glanbia (OTC:GLAPF, OTCPK:GLAPY), Grifols (NASDAQ:GRFS), Imperial Brands (OTCQX:IMBBY, OTCQX:ITYBF), Johnson & Johnson (NYSE:JNJ), Ahold (OTCQX:AHONY, OTCQX:AHODF, OTCQX:AHOND), LabCorp (NYSE:LH), Perrigo (NYSE:PRGO), Telus (NYSE:TU), Unilever (UL, UN), UnitedHealth Group (NYSE:UNH)
    • See full table here.
    | Sun, Jul. 3, 2:50 PM | 14 Comments
  • Fri, Jun. 24, 7:01 AM
    • Cerner (NASDAQ:CERN) upgraded to Buy from Neutral with $65 (14% upside) price target by SunTrust Robinson.
    • Catalent (NYSE:CTLT) upgraded to Outperform from Market Perform with a $26 (midpoint)(10% upside) price target by Wells Fargo. Upgraded to Buy from Neutral by Bank of America.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $82 (17% upside) from $76.
    • Valeant Pharmaceuticals (NYSE:VRX) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $35 (57% upside) from $50.
    • AveXis (NASDAQ:AVXS) downgraded to Hold from Buy by Jefferies. Price target lowered to $39 (3% downside risk) from $42.
    • Surgical Care Affiliates (NASDAQ:SCAI) downgraded to Neutral from Buy by JPMorgan. Price target maintained at $48 (3% upside).
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) downgraded to Neutral from Buy by Bank of America.
    • Express Scripts Holdings (NASDAQ:ESRX) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target raised to $70 (9% downside risk) from $67.
    • Perrigo (NYSE:PRGO) downgraded to Hold from Buy by Argus Research.
    • CVS Health (NYSE:CVS) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $104 (11% upside) from $111.
    | Fri, Jun. 24, 7:01 AM | 19 Comments